131 related articles for article (PubMed ID: 37827277)
1. Topical Application of a PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL-4 Production.
Takahashi K; Miyake K; Ito J; Shimamura H; Suenaga T; Karasuyama H; Ohashi K
J Invest Dermatol; 2024 May; 144(5):1048-1057.e8. PubMed ID: 37827277
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
[TBL] [Abstract][Full Text] [Related]
3. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
[TBL] [Abstract][Full Text] [Related]
6. Skin-infiltrating basophils promote atopic dermatitis-like inflammation via IL-4 production in mice.
Yamanishi Y; Mogi K; Takahashi K; Miyake K; Yoshikawa S; Karasuyama H
Allergy; 2020 Oct; 75(10):2613-2622. PubMed ID: 32406065
[TBL] [Abstract][Full Text] [Related]
7. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
8. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Ahluwalia J; Udkoff J; Waldman A; Borok J; Eichenfield LF
Drugs; 2017 Sep; 77(13):1389-1397. PubMed ID: 28681318
[TBL] [Abstract][Full Text] [Related]
10. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
[TBL] [Abstract][Full Text] [Related]
11. Basophils promote barrier dysfunction and resolution in the atopic skin.
Pellefigues C; Naidoo K; Mehta P; Schmidt AJ; Jagot F; Roussel E; Cait A; Yumnam B; Chappell S; Meijlink K; Camberis M; Jiang JX; Painter G; Filbey K; Uluçkan Ö; Gasser O; Le Gros G
J Allergy Clin Immunol; 2021 Sep; 148(3):799-812.e10. PubMed ID: 33662369
[TBL] [Abstract][Full Text] [Related]
12. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
Saeki H; Ito K; Yokota D; Tsubouchi H
J Am Acad Dermatol; 2022 Mar; 86(3):607-614. PubMed ID: 34710557
[TBL] [Abstract][Full Text] [Related]
13. IL-37 Targets TSLP-Primed Basophils to Alleviate Atopic Dermatitis.
Hou T; Tsang MS; Kan LL; Li P; Chu IM; Lam CW; Wong CK
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299012
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibition by difamilast regulates filaggrin and loricrin expression via keratinocyte proline-rich protein in human keratinocytes.
Tsuji G; Hashimoto-Hachiya A; Yumine A; Takemura M; Kido-Nakahara M; Ito T; Yamamura K; Nakahara T
J Dermatol Sci; 2023 May; 110(2):61-68. PubMed ID: 37156706
[TBL] [Abstract][Full Text] [Related]
15. Eosinophils Mediate Basophil-Dependent Allergic Skin Inflammation in Mice.
Eberle JU; Radtke D; Nimmerjahn F; Voehringer D
J Invest Dermatol; 2019 Sep; 139(9):1957-1965.e2. PubMed ID: 30910757
[TBL] [Abstract][Full Text] [Related]
16. Difamilast for the treatment of atopic dermatitis.
Freitas E; Torres T
J Int Med Res; 2023 Jun; 51(6):3000605231169445. PubMed ID: 37389929
[TBL] [Abstract][Full Text] [Related]
17. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Purushothaman B; Arumugam P; Kulsi G; Song JM
Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
[TBL] [Abstract][Full Text] [Related]
19. Basophil-derived IL-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy.
Hussain M; Borcard L; Walsh KP; Pena Rodriguez M; Mueller C; Kim BS; Kubo M; Artis D; Noti M
J Allergy Clin Immunol; 2018 Jan; 141(1):223-234.e5. PubMed ID: 28390860
[TBL] [Abstract][Full Text] [Related]
20. Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis.
Nakashima C; Otsuka A; Kitoh A; Honda T; Egawa G; Nakajima S; Nakamizo S; Arita M; Kubo M; Miyachi Y; Kabashima K
J Allergy Clin Immunol; 2014 Jul; 134(1):100-7. PubMed ID: 24713170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
